Skip to main content

Poster: Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2B Studies

Lead Author: Marilyn Tan, MD, FACE (Presenter)

Published: Endocrine Society’s Annual Meeting (ENDO 2025)

Date: July 13, 2025

Read more (opens new window)

Presentation: Reduction in Rate of Hypoglycemic Events with Avexitide in Post-Bariatric Hypoglycemia: Results from the Phase 2 and 2B Studies

Lead Author: Marilyn Tan, MD, FACE (Presenter)

Published: Endocrine Society’s Annual Meeting (ENDO 2025)

Date: July 13, 2025

Read more (opens new window)

Population PK (PopPK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of Avexitide in Individuals with Post-Bariatric Hypoglycemia

Lead Author: Kelly Fox, MD (Presenter)

Published: Endocrine Society’s Annual Meeting (ENDO 2025)

Date: July 12, 2025

Read more (opens new window)

A Phase 1, Multicenter, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in ALS (LUMINA)

Lead Author: Sabrina Paganoni, MD, PhD

Published: The Canadian Neurological Sciences Federation (CNSF) Congress

Date: June 11, 2025

Read more (opens new window)

Survival Results from the Global Phase 3 Trial (PHOENIX) Evaluating Sodium Phenylbutyrate and Ursodoxicoltaurine in ALS

Lead Author: Leonard H. van den Berg, MD, PhD (Presenter)

Published: European Network to Cure ALS (ENCALS) 2025 Meeting

Date: June 5, 2025

Read more (opens new window)

48-Week Results from the HELIOS Trial: A Phase 2, Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome

Lead Author: Fumihiko Urano, MD, PhD

Published: Joint Congress of the European Society for Pediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE)

Date: May 12, 2025

Read more (opens new window)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Post-Bariatric Hypoglycemia (LUCIDITY)

Lead Author: Ryan Miller, MD

Published: World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Date: December 12, 2024

Read more (opens new window)

Amylyx Update on Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2

Lead Author: Lauren Kett, MD, PhD (Presenter)

Published: ALS ONE’s 7th Annual ALS Research Symposium

Date: November 14, 2024

Read more (opens new window)

Results from the HELIOS Trial: A Phase 2 Open-Label Study Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Wolfram Syndrome

Lead Author: Amy Viehoever, MD, PhD (Presenter)

Published: Child Neurology Society Annual Meeting

Date: November 11 - 14, 2024

Read more (opens new window)

A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in Amyotrophic Lateral Sclerosis (LUMINA)

Lead Author: Lauren Kett, MD, PhD (Presenter)

Published: Northeast ALS Consortium (NEALS) Annual Meeting

Date: October 23, 2024

Read more (opens new window)